ZA200404067B - Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methy}-phenoxyl)-acetic acid. - Google Patents

Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methy}-phenoxyl)-acetic acid. Download PDF

Info

Publication number
ZA200404067B
ZA200404067B ZA200404067A ZA200404067A ZA200404067B ZA 200404067 B ZA200404067 B ZA 200404067B ZA 200404067 A ZA200404067 A ZA 200404067A ZA 200404067 A ZA200404067 A ZA 200404067A ZA 200404067 B ZA200404067 B ZA 200404067B
Authority
ZA
South Africa
Prior art keywords
methyl
pyridine
amino
phenoxy
sulfonyl
Prior art date
Application number
ZA200404067A
Other languages
English (en)
Inventor
Kimberly O'keefe Cameron
Kim Anne Johnson
Bruce Allen Lefker
Chandra Aggarwal Prakash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200404067B publication Critical patent/ZA200404067B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200404067A 2002-01-31 2004-05-25 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methy}-phenoxyl)-acetic acid. ZA200404067B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35374802P 2002-01-31 2002-01-31

Publications (1)

Publication Number Publication Date
ZA200404067B true ZA200404067B (en) 2005-08-29

Family

ID=27663249

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200404067A ZA200404067B (en) 2002-01-31 2004-05-25 Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methy}-phenoxyl)-acetic acid.

Country Status (29)

Country Link
US (1) US6852863B2 (pt)
EP (1) EP1470109A1 (pt)
JP (1) JP2005521668A (pt)
KR (1) KR20040077884A (pt)
CN (1) CN1625549A (pt)
AP (1) AP2004003094A0 (pt)
AR (1) AR038332A1 (pt)
BR (1) BR0307339A (pt)
CA (1) CA2473984A1 (pt)
EA (1) EA200400724A1 (pt)
EC (1) ECSP045215A (pt)
GB (1) GB2400100B (pt)
HN (1) HN2003000051A (pt)
HR (1) HRP20040683A2 (pt)
HU (1) HUP0500012A2 (pt)
IL (1) IL162167A0 (pt)
IS (1) IS7281A (pt)
MA (1) MA27169A1 (pt)
MX (1) MXPA04004960A (pt)
NO (1) NO20043569D0 (pt)
OA (1) OA12760A (pt)
PA (1) PA8564601A1 (pt)
PE (1) PE20030978A1 (pt)
PL (1) PL371982A1 (pt)
TN (1) TNSN04138A1 (pt)
TW (1) TW200302080A (pt)
UY (1) UY27632A1 (pt)
WO (1) WO2003064391A1 (pt)
ZA (1) ZA200404067B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US7666330B2 (en) * 2005-04-20 2010-02-23 Lg Chem, Ltd. Additive for non-aqueous electrolyte and secondary battery using the same
BRPI0714683A2 (pt) * 2006-07-28 2013-03-26 Pfizer Prod Inc agonistas ep2
AU2008226947B2 (en) 2007-03-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009113600A1 (ja) * 2008-03-12 2009-09-17 宇部興産株式会社 ピリジルアミノ酢酸化合物
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
HUE026742T2 (en) 2009-03-30 2016-07-28 Ube Industries A pharmaceutical composition for the treatment or prevention of glaucoma
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)

Also Published As

Publication number Publication date
HUP0500012A2 (hu) 2005-04-28
US20030216445A1 (en) 2003-11-20
OA12760A (en) 2006-07-04
NO20043569L (no) 2004-08-26
AR038332A1 (es) 2005-01-12
TNSN04138A1 (fr) 2007-03-12
HN2003000051A (es) 2003-09-24
US6852863B2 (en) 2005-02-08
MXPA04004960A (es) 2005-04-08
CA2473984A1 (en) 2003-08-07
UY27632A1 (es) 2003-08-29
AP2004003094A0 (en) 2004-09-30
GB2400100B (en) 2006-04-12
TW200302080A (en) 2003-08-01
IL162167A0 (en) 2005-11-20
MA27169A1 (fr) 2005-01-03
PE20030978A1 (es) 2003-11-19
NO20043569D0 (no) 2004-08-26
PL371982A1 (en) 2005-07-11
KR20040077884A (ko) 2004-09-07
WO2003064391A1 (en) 2003-08-07
PA8564601A1 (es) 2003-09-05
ECSP045215A (es) 2004-09-28
CN1625549A (zh) 2005-06-08
BR0307339A (pt) 2004-12-07
EP1470109A1 (en) 2004-10-27
JP2005521668A (ja) 2005-07-21
EA200400724A1 (ru) 2004-12-30
HRP20040683A2 (en) 2004-10-31
GB0413967D0 (en) 2004-07-28
IS7281A (is) 2004-05-21
GB2400100A (en) 2004-10-06

Similar Documents

Publication Publication Date Title
US6852863B2 (en) Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
TWI793511B (zh) Glp-1r調節化合物
DE69736007T2 (de) Vorbeugung des verlustes und wiederherstellung von knochenmasse unter verwendung von prostaglandin-analogen
DE69836752T2 (de) Prostaglandin-Agonisten und deren Verwendung zur Behandlung von Knochenerkrankungen
JP2021512068A (ja) 置換ピリダジノン化合物
US6100403A (en) Production of benzaldehyde compounds
CN102498100A (zh) 抗病毒杂环化合物
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
JP3080405B2 (ja) アミノスチルバゾール誘導体及び医薬
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
EP4289841A1 (en) Benzo seven-membered ring bifunctional compound and application thereof
US20010041725A1 (en) Novel urea derivatives having nitrogen aromatic heterocycle
CN105175309A (zh) N-苄基-5/6-甲酰氨基吲哚-2-羧酸衍生物及其用途
AU2003239465A1 (en) Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
JPH07503006A (ja) 認識力強化剤としてのジ置換多環式化合物
EP1403249B1 (en) Cyclic diamine compounds bearing six-membered cyclic groups
EP0532550A1 (en) Benzoic acid derivatives for treating leukotriene-related diseases
JP2009137934A (ja) プロスタグランジン作動薬の多形体およびそれらを製造するための方法
HUT64521A (en) Process for producing amidic bound pyridyl-benzoic acid derivatives and pharmaceutical preparatives containing them
EP3891155B1 (en) 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
EP0532634A1 (en) Phthalamic acids and their isomers for treating leukotriene-related diseases
WO2009027803A2 (en) Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
US20110046385A1 (en) Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
CZ20001280A3 (cs) Agonisté prostaglandinu a jejich použití pro léčení chorob kostí